Ireland - English - HPRA (Health Products Regulatory Authority)

pharmacia laboratories limited - emepronium bromide - tablets - 100 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmacia laboratories limited - emepronium bromide - tablets - 200 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

pharmacia laboratories limited - emepronium carrageenate - tablets - 250 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - emepronium carrageenate 333mg equivalent to 200 mg emepronium bromide - tablet - 200 mg - active: emepronium carrageenate 333mg equivalent to 200 mg emepronium bromide excipient: colloidal silicon dioxide crospovidone ethylcellulose glycerol hyprolose macrogol 8000 magnesium stearate   microcrystalline cellulose sorbitan oleate titanium dioxide vanillin

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - cetirizine hydrochloride, quantity: 1 mg/ml - oral liquid - excipient ingredients: purified water; saccharin sodium; propyl hydroxybenzoate; propylene glycol; glycerol; glacial acetic acid; methyl hydroxybenzoate; sorbitol solution (70 per cent) (non-crystallising); sodium acetate trihydrate; flavour - seasonal allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with seasonal allergic rhinitis (hay fever) in adults and children aged 1-12 years. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing and redness of the eyes. perennial allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children aged 1-12 years. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing. chronic idiopathic urticaria: cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children aged 1-12 years. it significantly reduces the occurrence, severity and duration of hives and markedly reduces pruritus. as with other antihistamines, patients should be advised to seek medical advice about the possibility that their urticar

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - cetirizine hydrochloride, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); propylene glycol; glycerol; propyl hydroxybenzoate; methyl hydroxybenzoate; sodium citrate dihydrate; citric acid monohydrate; purified water; flavour - seasonal allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with seasonal allergic rhinitis (hay fever) in adults and children aged 1-12 years. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing and redness of the eyes. , perennial allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children aged 1-12 years. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing. , chronic idiopathic urticaria: cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children aged 1-12 years. it significantly reduces the occurrence, severity and duration of hives and markedly reduces pruritus. as with other antihistamines, patients should be advised to seek medical advice about the possibility that their urt

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - cetirizine hydrochloride, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; sodium citrate dihydrate; citric acid monohydrate; methyl hydroxybenzoate; purified water; sorbitol solution (70 per cent) (non-crystallising); propyl hydroxybenzoate; glycerol; flavour - seasonal allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with seasonal allergic rhinitis (hay fever) in adults and children aged 1-12 years. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing and redness of the eyes. , perennial allergic rhinitis: cetirizine is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children aged 1-12 years. symptoms treated effectively include sneezing, rhinorrhoea, post-nasal discharge, nasal pruritus, ocular pruritus and tearing. , chronic idiopathic urticaria: cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children aged 1-12 years. it significantly reduces the occurrence, severity and duration of hives and markedly reduces pruritus. as with other antihistamines, patients should be advised to seek medical advice about the possibility that their urt

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablets is contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2) ]. patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis. children 6 months to 11 years of age with impaired renal function. pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, levocetirizine dihydrochloride

United States - English - NLM (National Library of Medicine)

micro labs limited - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 years of age and older. levocetirizine dihydrochloride tablets are indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. the use of levocetirizine dihydrochloride tablets are contraindicated in: patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions ( 6.2) ]. patients with end-stage renal disease (cl cr < 10 ml/min) and patients undergoing hemodialysis children 6 months to 11 years of age with impaired renal function risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pinewood healthcare - cetirizine hydrochloride - oral solution - 1mg/1ml